Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Douglas, Donna N ^a   Kawahara, Toshiyasu ^a   Sis, Banu ^b   Bond, David ^a   Fischer, Karl P ^a   Lorne J Tyrrell, D ^a,c   Lewis, Jamie T ^a   Kneteman, Norman M ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c KMT Hepatech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE; THYMIDINE KINASE; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMISTRY; BYSTANDER EFFECT; CAUSE OF DEATH; CELL KILLING; CLINICAL ASSESSMENT; CYTOTOXICITY; DRUG SENSITIZATION; FEMALE; HEPATOCYTE TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INDUCIBLE LIVER DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SCID MOUSE; SERUM GROUP GC SYSTEM; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ANIMAL; CELL LINE; CELL SURVIVAL; CELL TRANSPLANTATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HERPES SIMPLEX VIRUS 1; IMMUNOBLOTTING; LIVER; LIVER CELL; METABOLISM; METHODOLOGY; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSPLANTATION; TUMOR CELL LINE; ULTRASTRUCTURE; XENOGRAFT;

ANIMALIA; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 1; MURINAE; MUS;

ANIMALS; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; GANCICLOVIR; HEPATOCYTES; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOBLOTTING; LIVER; LIVER DISEASES; MALE; MICE; MICE, SCID; MICE, TRANSGENIC; MICROSCOPY, ELECTRON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYMIDINE KINASE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77949517188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009209     Document Type: Article

References (59)

1. Rodrigues AD (1994) Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem Pharmacol 48: 197-200.
2. Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JT, et al. (1994) Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. Anal Biochem 219: 309-320.
3. Rodrigues AD, Wong SL (1997) Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 43: 65-101.
4. Barry M, Feely J (1990) Enzyme induction and inhibition. Pharmacol Ther 48: 71-94.
5. Park BK, Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1-24.
6. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R (2003) Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4: 292-312.
7. Rodrigues AD, Rushmore TH (2002) Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab 3: 289-309.
8. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, et al. (2001) Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7: 927-933.
9. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, et al. (1991) Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66: 245-256.
10. Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL (1994) Replacement of diseased mouse liver by hepatic cell transplantation. Science 263: 1149-1152.
11. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165: 901-912.
12. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, et al. (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29: 1316-1324.
13. Fausto N (2000) Liver regeneration. J Hepatol 32: 19-31.
14. Fausto N (2001) Liver regeneration: from laboratory to clinic. Liver Transpl 7: 835-844.
15. Fausto N, Riehle KJ (2005) Mechanisms of liver regeneration and their clinical implications. J Hepatobiliary Pancreat Surg 12: 181-189.
16. Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276: 60-66.
17. Myronovych A, Murata S, Chiba M, Matsuo R, Ikeda O, et al. (2008) Role of platelets on liver regeneration after 90% hepatectomy in mice. J Hepatol 49: 363-372.
18. Fillat C, Carrio M, Cascante A, Sangro B (2003) Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3: 13-26.
19. Braun KM, Degen JL, Sandgren EP (2000) Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells. Nat Med 6: 320-326.
20. Zhang Y, Huang SZ, Wang S, Zeng YT (2005) Development of an HSV-tk transgenic mouse model for study of liver damage. Febs J 272: 2207-2215.
21. Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333: 1118-1127.
22. Al-Shawi R, Burke J, Jones CT, Simons JP, Bishop JO (1988) A Mup promoter-thymidine kinase reporter gene shows relaxed tissue-specific expression and confers male sterility upon transgenic mice. Mol Cell Biol 8: 4821-4828.
23. Braun RE, Lo D, Pinkert CA, Widera G, Flavell RA, et al. (1990) Infertility in male transgenic mice: disruption of sperm development by HSV-tk expression in postmeiotic germ cells. Biol Reprod 43: 684-693.
24. Ellison AR, Wallace H, al-Shawi R, Bishop JO (1995) Different transmission rates of herpesvirus thymidine kinase reporter transgenes from founder male parents and male parents of subsequent generations. Mol Reprod Dev 41: 425-434.
25. Huttner KM, Pudney J, Milstone DS, Ladd D, Seidman JG (1993) Flagellar and acrosomal abnormalities associated with testicular HSV-tk expression in the mouse. Biol Reprod 49: 251-261.
26. Sandgren EP, Palmiter RD, Heckel JL, Brinster RL, Degen JL (1992) DNA rearrangement causes hepatocarcinogenesis in albumin-plasminogen activator transgenic mice. Proc Natl Acad Sci U S A 89: 11523-11527.
27. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281.
28. Brand T, Andree B, Schneider A, Buchberger A, Arnold HH (1997) Chicken NKx2-8, a novel homeobox gene expressed during early heart and foregut development. Mech Dev 64: 53-59.
29. Sterman DH, Kaiser LR, Albelda SM (1998) Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12: 553-568.
30. Thust R, Tomicic M, Klocking R, Wutzler P, Kaina B (2000) Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir. Mutagenesis 15: 177-184.
31. van der Eb MM, Cramer SJ, Vergouwe Y, Schagen FH, van Krieken JH, et al. (1998) Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther 5: 451-458.
32. Wallace H, Clarke AR, Harrison DJ, Hooper ML, Bishop JO (1996) Ganciclovir-induced ablation non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis. Oncogene 13: 55-61.
33. Bi WL, Parysek LM, Warnick R, Stambrook PJ (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 4: 725-731.
34. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, et al. (1997) Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 57: 1523-1528.
35. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, et al. (1996) Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3: 85-92.
36. Fick J, Barker FG, 2nd, Dazin P, Westphale EM, Beyer EC, et al. (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci U S A 92: 11071-11075.
37. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, et al. (1993) The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283.
38. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H (1996) Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 93: 1831-1835.
39. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53: 83-88.
40. Hamel W, Magnelli L, Chiarugi VP, Israel MA (1996) Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56: 2697-2702.
41. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, et al. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
42. Kaneko Y, Tsukamoto A (1995) Gene therapy of hepatoma: bystander effects and non-apoptotic cell death induced by thymidine kinase and ganciclovir. Cancer Lett 96: 105-110.
43. Izquierdo M, Martin V, de Felipe P, Izquierdo JM, Perez-Higueras A, et al. (1996) Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther 3: 491-495.
44. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, et al. (1998) A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 9: 2595-2604.
45. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, et al. (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39-69.
46. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, et al. (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 90: 7024-7028.
47. Barba D, Hardin J, Sadelain M, Gage FH (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 91: 4348-4352.
48. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ (1996) In situ use of suicide genes for cancer therapy. Semin Oncol 23: 31-45.
49. Bernardi P, Scorrano L, Colonna R, Petronilli V, Di Lisa F (1999) Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem 264: 687-701.
50. van der Eb MM, Geutskens SB, van Kuilenburg AB, van Lenthe H, van Dierendonck JH, et al. (2003) Ganciclovir nucleotides accumulate in mitochondria of rat liver cells expressing the herpes simplex virus thymidine kinase gene. J Gene Med 5: 1018-1027.
51. Shiota G, Kawasaki H, Nakamura T, Schmidt EV (1995) Down-regulation of cmyc mRNA after completion of liver regeneration in transgenic mice expressing hepatocyte growth factor in liver. Res Commun Mol Pathol Pharmacol 89: 259-268.
52. Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, et al. (2003) Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 284: 185-195.
53. Brinster RL, Chen HY, Trumbauer ME, Yagle MK, Palmiter RD (1985) Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. Proc Natl Acad Sci U S A 82: 4438-4442.
54. Araki R, Fujimori A, Hamatani K, Mita K, Saito T, et al. (1997) Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc Natl Acad Sci U S A 94: 2438-2443.
55. Blunt T, Gell D, Fox M, Taccioli GE, Lehmann AR, et al. (1996) Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci U S A 93: 10285-10290.
56. Meuleman P, Vanlandschoot P, Leroux-Roels G (2003) A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice. Biochem Biophys Res Commun 308: 375-378.
57. Kneteman NM, Weiner AJ, O'Connell J, Collett M, Gao T, et al. (2006) Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43: 1346-1353.
58. al-Shawi R, Burke J, Wallace H, Jones C, Harrison S, et al. (1991) The herpes simplex virus type 1 thymidine kinase is expressed in the testes of transgenic mice under the control of a cryptic promoter. Mol Cell Biol 11: 4207-4216.
59. Graham L, Orenstein JM (2007) Processing tissue and cells for transmission electron microscopy in diagnostic pathology and research. Nat Protoc 2: 2439-2450.